Gary Myer's questions to PROVECTUS BIOPHARMACEUTICALS (PVCT) leadership • Q1 2016
Question
Gary Myer from Myer Financial asked about the critical data points and triggers needed to secure a major strategic partner, referencing a Pfizer executive's stated interest in innovative immunotherapies suitable for combination therapies.
Answer
CTO Eric Wachter explained that the company's mechanism of action studies for both PH-10 and PV-10 are designed to highlight their innovative nature, immunology, and combination potential to align with the interests of partners. Interim CEO Peter Culpepper elaborated that PV-10's unique properties as an ablative immunotherapy make it a compelling candidate for numerous combination regimens, a key discussion point with potential Big Pharma partners.